Mitochon Pharmaceuticals, Inc.
Small-molecule therapeutics targeting mitochondrial dysfunction to restore ATP production and reduce oxidative stress and calcium overload
- Sector
- Biotech
- Headquarters
- RADNOR, PA
- Founded
- 2014
- Latest Form D
- $425K, Apr 2016
- Total capital
- $875K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $825K
- 2 Form D · last Apr 2016
- 126 months since last filing
- Federal contracts
- $50K
- 1 award · Defense
- Rank in Biotech#353 of 4373
- Granted patents
- 4
- 6 pending · first 2018
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Federal contractDefense · MP201 Drug Development/synthesis$50K
- Private capital raisedForm D · SEC · 2nd filing$425K
- Private capital raisedForm D · SEC · 1st filing$400K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Robert AlonsoResearcherExecutive Officer, DirectorLinked by 4 patents
- John GeislerExecutive Officer, DirectorNamed in SEC Form D filings
- John IrwinDirectorNamed in SEC Form D filings
- Peter CrooksExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 10- PendingInduced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesUSPTOApplication 18336440
- GrantedInduced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesUSPTOUS 11,717,497
- GrantedInduced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesUSPTOUS 10,864,173
Show all 10 patent records
- Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesMay 16, 2024 · Application 18336440Pending
- Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesAug 8, 2023 · US 11,717,497Granted
- Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesDec 15, 2020 · US 10,864,173Granted
- Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesMar 5, 2019 · US 10,220,006Granted
- Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic DiseasesMay 22, 2018 · US 9,974,755Granted
- 2,4 Dnp And Prodrugs Thereof For Treatment Of Pulmonary And Autoimmune DiseasesApplication PCTUS2023065876Pending
- 2,4 Dnp And Prodrugs Thereof For Treatment Of CancerApplication PCTUS2022039419Pending
- Induced Expression Of Brain Derived Neurotrophic Factor (bdnf) For Treatment Of Neuromuscular, Neurodegenerative, Autoimmune, Developmental And/or Metabolic DiseasesApplication PCTUS2016014312Pending
- 2,4 DNP and Prodrugs Thereof for Treatment of Pulmonary and Autoimmune DiseasesApplication 63332083Pending
- 2,4 DNP and Prodrugs Thereof for Treatment of Cancer and PainApplication 63229468Pending
Related companies, and why
- LEADSCOPE, INC.Similar federal contract value in Biotech · $62K in contracts
- Emmaus Life Sciences, Inc.Similar federal contract value in Biotech · $60K in contracts
- Transposagen Biopharmaceuticals, Inc.Similar federal contract value in Biotech · $56K in contracts
- Oralome IncSimilar federal contract value in Biotech · $50K in contracts
- AlleviSimilar federal contract value in Biotech · $49K in contracts
- Ichor Life Sciences, Inc.Similar federal contract value in Biotech · $47K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .